Medivir: The Board Member Niklas Prager appointed new president from 9.1
2014-08-11 08:40
(SIX) board of Medivir today announced that it has appointed Niklas Prager new president and CEO. Prager will from 1st september in 2014. It appears from a statement. Prager has during her career worked primarily within pharmaceutical industry in a variety of positions, including as employee of Merck in the United States and Sweden, as well as CEO of Pfizer (AB), Envirotainer and Qbtech. According to the Board, he is also "well versed" in Medivir's operations from his time as Chairman of BioPhausia and he was elected to the Medivir's Board in May of this year. In connection with the Prager takes position as president and CEO, he leaves the board of Medivir. "Medivir is an attractive company that is in an exciting development after the successful market launch of simeprevir. Together with the Board and Medivir qualified scientists and staff, I will focus on further developing and highlight the value of the company. An update of Medivir strategic plan is a top priority, and this work is already underway fully, "says Niklas Prager in a comment. Johan Eklund, +46 31 350 64 87 mailto: johan.eklund@six-group.se www.blogg.six.seSIXNews SIX News
No comments:
Post a Comment